Will the EU’s SPC manufacturing waiver weaken European pharma’s IP?
Despite dire warnings by the US Chamber of Commerce, the impact of the EU’s SPC waiver won’t be known for years, says Paul Williams of Lewis Silkin.
- Royalty Pharma: welcome clarity mixed with unwelcome ambiguity 15-05-2020
- Will Big Pharma get the bug for microbiome therapies? 06-05-2020
- Why things could get ugly over COVID-19 patents 30-04-2020
- COVID-19: governments look to shield companies from IP enforcement 23-04-2020
- Patent pools: should rights owners give up their IP? 21-04-2020
Latest news
Teva to face inhaler infringement allegations in UK court
03-06-2020
Israeli generic drugmaker Teva Pharmaceuticals must face infringement claims related to an asthma inhaler, an English judge has ruled.
